The classification of breast cancer affects treatment decision and prognosis: hormone-based therapy for ER+ patients; targeted therapy for HER2+ patients; and poorly differentiated cancer often has the worse prognosis (5–7). Here, ERBB2 is linked to breast carcinoma.